CG Oncology, Inc. Research and Development Expense
CG Oncology, Inc. (CGON) reported Research and Development Expense of $54.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- CG Oncology, Inc. research and development expense for the quarter ending 2026-06-30 was $54.66M, a 74.45% increase year-over-year.
- CG Oncology, Inc. research and development expense for the quarter ending 2026-03-31 was $43.73M, a 59.21% increase year-over-year.
- CG Oncology, Inc. research and development expense for the quarter ending 2025-12-31 was $29.96M, a 11.78% increase year-over-year.
- CG Oncology, Inc. research and development expense for the quarter ending 2025-09-30 was $27.88M, a 42.11% increase year-over-year.
- CG Oncology, Inc. research and development expense for fiscal 2025 was $116.64M, a 42.07% increase from fiscal 2024.
- CG Oncology, Inc. research and development expense for fiscal 2024 was $82.10M, a 79.45% increase from fiscal 2023.
- CG Oncology, Inc. research and development expense for fiscal 2023 was $45.75M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.66M 10-Q · filed 2026-08-06 | $98.39M 10-Q · filed 2026-08-06 | $128.34M derived: sum of 3 quarters · filed 2026-08-06 | $156.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $43.73M 10-Q · filed 2026-05-08 | $73.69M derived: sum of 2 quarters · filed 2026-05-08 | $101.57M derived: sum of 3 quarters · filed 2026-05-08 | $132.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $29.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $57.84M derived: sum of 2 quarters · filed 2026-02-27 | $89.17M derived: sum of 3 quarters · filed 2026-08-06 | $116.64M 10-K · filed 2026-02-27 |
| 2025-09-30 | $27.88M 10-Q · filed 2025-11-14 | $59.22M derived: sum of 2 quarters · filed 2026-08-06 | $86.68M 10-Q · filed 2025-11-14 | $113.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $31.33M 10-Q · filed 2026-08-06 | $58.80M 10-Q · filed 2026-08-06 | $85.60M derived: sum of 3 quarters · filed 2026-08-06 | $105.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $27.47M 10-Q · filed 2026-05-08 | $54.27M derived: sum of 2 quarters · filed 2026-05-08 | $73.89M derived: sum of 3 quarters · filed 2026-05-08 | $92.36M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $26.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $46.42M derived: sum of 2 quarters · filed 2026-02-27 | $64.89M derived: sum of 3 quarters · filed 2026-02-27 | $82.10M 10-K · filed 2026-02-27 |
| 2024-09-30 | $19.62M 10-Q · filed 2025-11-14 | $38.09M derived: sum of 2 quarters · filed 2025-11-14 | $55.30M 10-Q · filed 2025-11-14 | $71.64M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $18.47M 10-Q · filed 2025-08-08 | $35.68M 10-Q · filed 2025-08-08 | $52.02M derived: sum of 3 quarters · filed 2026-02-27 | $63.76M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $17.21M 10-Q · filed 2025-05-13 | $33.55M derived: sum of 2 quarters · filed 2026-02-27 | $45.28M derived: sum of 3 quarters · filed 2026-02-27 | $55.12M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $16.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $28.07M derived: sum of 2 quarters · filed 2026-02-27 | $37.91M derived: sum of 3 quarters · filed 2026-02-27 | $45.75M 10-K · filed 2026-02-27 |
| 2023-09-30 | $11.73M 10-Q · filed 2024-11-12 | $21.57M derived: sum of 2 quarters · filed 2024-11-12 | $29.41M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $9.83M 10-Q · filed 2024-08-08 | $17.68M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $7.84M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |